Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens

Authors: Al Muktafi Sadi, Dong-Yu Wang, Bruce J Youngson, Naomi Miller, Scott Boerner, Susan J Done, Wey L Leong

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

The ability of gene profiling to predict treatment response and prognosis in breast cancers has been demonstrated in many studies using DNA microarray analyses on RNA from fresh frozen tumor specimens. In certain clinical and research situations, performing such analyses on archival formalin fixed paraffin-embedded (FFPE) surgical specimens would be advantageous as large libraries of such specimens with long-term follow-up data are widely available. However, FFPE tissue processing can cause fragmentation and chemical modifications of the RNA. A number of recent technical advances have been reported to overcome these issues. Our current study evaluates whether or not the technology is ready for clinical applications.

Methods

A modified RNA extraction method and a recent DNA microarray technique, cDNA-mediated annealing, selection, extension and ligation (DASL, Illumina Inc) were evaluated. The gene profiles generated from FFPE specimens were compared to those obtained from paired fresh fine needle aspiration biopsies (FNAB) of 25 breast cancers of different clinical subtypes (based on ER and Her2/neu status). Selected RNA levels were validated using RT-qPCR, and two public databases were used to demonstrate the prognostic significance of the gene profiles generated from FFPE specimens.

Results

Compared to FNAB, RNA isolated from FFPE samples was relatively more degraded, nonetheless, over 80% of the RNA samples were deemed suitable for subsequent DASL assay. Despite a higher noise level, a set of genes from FFPE specimens correlated very well with the gene profiles obtained from FNAB, and could differentiate breast cancer subtypes. Expression levels of these genes were validated using RT-qPCR. Finally, for the first time we correlated gene expression profiles from FFPE samples to survival using two independent microarray databases. Specifically, over-expression of ANLN and KIF2C, and under-expression of MAPT strongly correlated with poor outcomes in breast cancer patients.

Conclusion

We demonstrated that FFPE specimens retained important prognostic information that could be identified using a recent gene profiling technology. Our study supports the use of FFPE specimens for the development and refinement of prognostic gene signatures for breast cancer. Clinical applications of such prognostic gene profiles await future large-scale validation studies.
Appendix
Available only for authorised users
Literature
1.
van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRef
2.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed
3.
van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008, 452: 564-570. 10.1038/nature06915.CrossRefPubMed
4.
Lassmann S, Kreutz C, Schoepflin A, Hopt U, Timmer J, Werner M: A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens. J Mol Med. 2009, 87: 211-224. 10.1007/s00109-008-0419-y.CrossRefPubMed
5.
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008, 359: 1995-2004. 10.1056/NEJMoa0804525.CrossRefPubMedPubMedCentral
6.
Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ: Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006, 7: 278-10.1186/1471-2164-7-278.CrossRefPubMedPubMedCentral
7.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
8.
Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005, 102: 3738-3743. 10.1073/pnas.0409462102.CrossRefPubMedPubMedCentral
9.
Troester MA, Hoadley KA, Sørlie T, Herbert BS, Børresen-Dale AL, Lønning PE, Shay JW, Kaufmann WK, Perou CM: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004, 64: 4218-4226. 10.1158/0008-5472.CAN-04-0107.CrossRefPubMed
10.
Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K: Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999, 27: 4436-4443. 10.1093/nar/27.22.4436.CrossRefPubMedPubMedCentral
11.
Balogh GA, Russo J, Mailo DA, Heulings R, Russo PA, Morrison P, Sheriff F, Russo IH: The breast of parous women without cancer has a different genomic profile compared to those with cancer. Int J Oncol. 2007, 31: 1165-1175.PubMed
12.
Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol. 2001, 158: 419-429. 10.1016/S0002-9440(10)63985-5.CrossRefPubMedPubMedCentral
13.
14.
Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol. 2008, 26: 729-735. 10.1200/JCO.2007.14.3222.CrossRefPubMed
15.
Duenwald S, Zhou M, Wang Y, Lejnine S, Kulkarni A, Graves J, Smith R, Castle J, Tokiwa G, Fine B, Dai H, Fare T, Marton M: Development of a microarray platform for FFPET profiling: Application to the classification of human tumors. J Transl Med. 2009, 7: 65-10.1186/1479-5876-7-65.CrossRefPubMedPubMedCentral
16.
Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y, Fan JB: Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol. 2004, 165: 1799-1807. 10.1016/S0002-9440(10)63435-9.CrossRefPubMedPubMedCentral
17.
Ravo M, Mutarelli M, Ferraro L, Grober OM, Paris O, Tarallo R, Vigilante A, Cimino D, De Bortoli M, Nola E, Cicatiello L, Weisz A: Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest. 2008, 88: 430-440. 10.1038/labinvest.2008.11.CrossRefPubMed
18.
Lee J, Hever A, Willhite D, Zlotnik A, Hevezi P: Effects of RNA degradation on gene expression analysis of human postmortem tissues. FASEB J. 2005, 19: 1356-1358.CrossRefPubMed
19.
Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J, da Silva L, Vargas AC, Reid L, kConFab Investigators, Simpson PT, Lakhani SR, Chenevix-Trench G: Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J Pathol. 2010, 221: 452-461.PubMed
20.
Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, Clarke C, Lakhani SR, Simpson PT: Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2008, 32: 773-783. 10.1097/PAS.0b013e318158d6c5.CrossRefPubMed
21.
Ton CC, Vartanian N, Chai X, Lin MG, Yuan X, Malone KE, Li CI, Dawson A, Sather C, Delrow J, Hsu L, Porter PL: Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL®sample preparation. Breast Cancer Res Treat.
22.
Mulligan JM, McDyer F, Deharo S, Farztdinov V, Halfpenny I, Delaney T, Couch F, Quinn JE, Harkin P, Kennedy R: Identification of molecular subtypes within a formalin-fixed, paraffin-embedded breast cancer tumour cohort [abstract]. Breast Cancer Res. 2010, 12 (Suppl 1): 33-10.1186/bcr2530.CrossRef
23.
Wong V, Wang DY, Warren K, Kulkarni S, Boerner S, Done SJ, Leong WL: The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers. BMC Cancer. 2008, 8: 277-10.1186/1471-2407-8-277.CrossRefPubMedPubMedCentral
24.
Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, Bouzyk M, Sledge GW, Moreno CS, Leyland-Jones B: Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques. 2008, 44: 417-423. 10.2144/000112703.CrossRefPubMedPubMedCentral
25.
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102: 13550-13555. 10.1073/pnas.0506230102.CrossRefPubMedPubMedCentral
26.
Rupp GM, Locker J: Purification and analysis of RNA from paraffin-embedded tissues. Biotechniques. 1988, 6: 56-60. 10.1038/nbt0188-56.PubMed
27.
Medeiros F, Rigl CT, Anderson GG, Becker SH, Halling KC: Tissue handling for genome-wide expression analysis: A review of the issues, evidence, and opportunities. Arch Pathol Lab Med. 2007, 131: 1805-1816.PubMed
28.
Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, Palma JF, Warrington JA: Tissue handling and specimen preparation in surgical pathology: Issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008, 132: 1929-1935.PubMed
29.
Ribeiro-Silva A, Zhang H, Jeffrey SS: RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: A comparison of column purification and magnetic bead-based technologies. BMC Mol Biol. 2007, 8: 118-10.1186/1471-2199-8-118.CrossRefPubMedPubMedCentral
30.
Linton K, Hey Y, Dibben S, Miller C, Freemont A, Radford J, Pepper S: Methods comparison for high-resolution transcriptional analysis of archival material on affymetrix plus 2.0 and exon 1.0 microarrays. Biotechniques. 2009, 47: 587-596. 10.2144/000113169.CrossRefPubMed
31.
Karsten SL, Van Deerlin VM, Sabatti C, Gill LH, Geschwind DH: An evaluation of tyramide signal amplification and archived fixed and frozen tissue in microarray gene expression analysis. Nucleic Acids Res. 2002, 30: E4-10.1093/nar/30.2.e4.CrossRefPubMedPubMedCentral
32.
Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, Sandler RS, Sharpless NE: RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest. 2007, 87: 383-391.PubMed
33.
Linton KM, Hey Y, Saunders E, Jeziorska M, Denton J, Wilson CL, Swindell R, Dibben S, Miller CJ, Pepper SD, Radford JA, Freemont AJ: Acquisition of biologically relevant gene expression data by affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer. 2008, 98: 1403-1414. 10.1038/sj.bjc.6604316.CrossRefPubMedPubMedCentral
34.
Paik S, Kim CY, Song YK, Kim WS: Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol. 2005, 2: 246-254.CrossRefPubMed
35.
Frank M, Doring C, Metzler D, Eckerle S, Hansmann ML: Global gene expression profiling of formalin-fixed paraffin-embedded tumor samples: A comparison to snap-frozen material using oligonucleotide microarrays. Virchows Arch. 2007, 450: 699-711. 10.1007/s00428-007-0412-9.CrossRefPubMed
36.
Farragher SM, Tanney A, Kennedy RD, Paul Harkin D: RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol. 2008, 130: 435-445. 10.1007/s00418-008-0479-7.CrossRefPubMed
37.
Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004, 164: 35-42. 10.1016/S0002-9440(10)63093-3.CrossRefPubMedPubMedCentral
38.
Olakowski M, Tyszkiewicz T, Jarzab M, Król R, Oczko-Wojciechowska M, Kowalska M, Kowal M, Gala GM, Kajor M, Lange D, Chmielik E, Gubala E, Lampe P, Jarzab B: NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma. Folia Histochem Cytobiol. 2009, 47: 249-255. 10.2478/v10042-009-0031-1.CrossRefPubMed
39.
Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R: Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008, 14: 4794-4799. 10.1158/1078-0432.CCR-08-0576.CrossRefPubMed
40.
Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, Park JH, Ueki T, Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T: Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 2008, 99: 62-70.PubMed
41.
Tanaka S, Nohara T, Iwamoto M, Sumiyoshi K, Kimura K, Takahashi Y: Tanigawa N. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol. 2009, 64: 341-346. 10.1007/s00280-008-0877-5.CrossRefPubMed
42.
Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S: The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res. 2010, 12: R43-10.1186/bcr2598.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens
Authors
Al Muktafi Sadi
Dong-Yu Wang
Bruce J Youngson
Naomi Miller
Scott Boerner
Susan J Done
Wey L Leong
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-253

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Genes Associated With Prognosis After Surgery For Malignant Pleural Mesothelioma Promote Tumor Cell Survival In Vitro

Research article

Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases

Research article

Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells

Research article

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Research article

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Research article

Decreased expression of 17β-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits